Vimarsana
Biggest News Aggregation in the World

Page 7 - Current Reports News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Current Reports. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Current Reports Today - Breaking & Trending Today

Definitive Healthcare Appoints Kevin Coop as CEO for Next Phase of Company's Growth - Vimarsana News

Definitive Healthcare Appoints Kevin Coop as CEO for Next Phase of Company's Growth

Mr. Coop brings more than 30 years of Operations, Product and Revenue ExpertiseFRAMINGHAM, Mass., May 28, 2024 -- Definitive Healthcare Corp. , an industry leader in healthcare commercial...

Longeveron® to Attend BIO International Convention 2024 - Vimarsana News

Longeveron® to Attend BIO International Convention 2024

MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that

MDWerks Common Stock Transitions to OTC Expert Market - Vimarsana News

MDWerks Common Stock Transitions to OTC Expert Market

GREEN COVE SPRINGS, Fla. - MDWerks, Inc. , a forward-thinking company leading the charge in the world of sustainable technology, today announced that its common stock has transitioned to trading on...

Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ... - Vimarsana News

Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ...

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven

Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting - Vimarsana News

Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

Consistent with short-term studies, KarXT was not associated with clinically meaningful changes in movement disorder scale scores and a low incidence rate of extrapyramidal symptoms was reported over...